24 November 2023
24 November 2023
The UK’s Autumn 2023 Statement takes a special interest in revitalising parts of the life sciences scene.
With more approved drugs coming through than ever before, the need to avoid confusing names to ensure patient safety is important.
Kaftrio in combination with ivacaftor will help enhance the quantity and function of the CFTR protein at the cell surface.
The oral IBD drug was first licensed to GSK in 2020 and is currently in Phase I clinical development.
EirGenix and Sandoz's biosimilar has been approved for all the indications as the reference biologic, Roche’s Herceptin.
T3 Pharma uses a bacterial secretion system for the delivery of immune-modulating proteins to cancer cells and tumour micro-environments.
The fast track designation for the paediatric multi-food allergy therapy ADP101 was based on the Phase I/II data.
Simcere will have the rights to develop and commercialise rademikibart in mainland China, Macau, Taiwan, and Hong Kong.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.
Give your business an edge with our leading industry insights.
